These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6208336)

  • 21. Serotonin in Alzheimer-type dementia and other dementing illnesses.
    Cross AJ
    Ann N Y Acad Sci; 1990; 600():405-15; discussion 415-7. PubMed ID: 1701291
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuropeptides in Alzheimer type dementia.
    Ferrier IN; Cross AJ; Johnson JA; Roberts GW; Crow TJ; Corsellis JA; Lee YC; O'Shaughnessy D; Adrian TE; McGregor GP
    J Neurol Sci; 1983 Dec; 62(1-3):159-70. PubMed ID: 6199464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia.
    Shimohama S; Taniguchi T; Fujiwara M; Kameyama M
    J Neurochem; 1986 Jan; 46(1):288-93. PubMed ID: 3940287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.
    Cheng AV; Ferrier IN; Morris CM; Jabeen S; Sahgal A; McKeith IG; Edwardson JA; Perry RH; Perry EK
    J Neurol Sci; 1991 Nov; 106(1):50-5. PubMed ID: 1779239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and regional distribution of serotonin S2-receptors in human brain.
    Schotte A; Maloteaux JM; Laduron PM
    Brain Res; 1983 Oct; 276(2):231-5. PubMed ID: 6627007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia.
    Allen JM; Ferrier IN; Roberts GW; Cross AJ; Adrian TE; Crow TJ; Bloom SR
    J Neurol Sci; 1984 Jun; 64(3):325-31. PubMed ID: 6147394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa.
    Davies P; Katzman R; Terry RD
    Nature; 1980 Nov; 288(5788):279-80. PubMed ID: 6107862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.
    Bowen DM; Najlerahim A; Procter AW; Francis PT; Murphy E
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9504-8. PubMed ID: 2574463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain.
    Allen SJ; Benton JS; Goodhardt MJ; Haan EA; Sims NR; Smith CC; Spillane JA; Bowen DM; Davison AN
    J Neurochem; 1983 Jul; 41(1):256-65. PubMed ID: 6134787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors.
    Battaglia G; Shannon M; Titeler M
    J Neurochem; 1984 Nov; 43(5):1213-9. PubMed ID: 6491656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adrenergic regulation of [3H]ketanserin binding sites during immobilization stress in the rat frontal cortex.
    Torda T; Murgas K; Cechova E; Kiss A; Saavedra JM
    Brain Res; 1990 Sep; 527(2):198-203. PubMed ID: 1701336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-molecular-weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome.
    Pierotti AR; Harmar AJ; Simpson J; Yates CM
    Neurosci Lett; 1986 Jan; 63(2):141-6. PubMed ID: 2869457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery.
    Battaglia G; Norman AB; Newton PL; Creese I
    J Neurochem; 1986 Feb; 46(2):589-93. PubMed ID: 2934516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia.
    Perry EK; Marshall E; Kerwin J; Smith CJ; Jabeen S; Cheng AV; Perry RH
    J Neurochem; 1990 Oct; 55(4):1454-6. PubMed ID: 1697897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.
    Bowen DM; Allen SJ; Benton JS; Goodhardt MJ; Haan EA; Palmer AM; Sims NR; Smith CC; Spillane JA; Esiri MM; Neary D; Snowdon JS; Wilcock GK; Davison AN
    J Neurochem; 1983 Jul; 41(1):266-72. PubMed ID: 6306169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism.
    Tamminga CA; Foster NL; Fedio P; Bird ED; Chase TN
    Neurology; 1987 Jan; 37(1):161-5. PubMed ID: 2879258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free amino acids in post-mortem cerebral cortices from patients with Alzheimer-type dementia.
    Arai H; Kobayashi K; Ichimiya Y; Kosaka K; Iizuka R
    Neurosci Res; 1985 Aug; 2(6):486-90. PubMed ID: 4047524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia.
    Shimohama S; Taniguchi T; Fujiwara M; Kameyama M
    J Neurochem; 1987 Apr; 48(4):1215-21. PubMed ID: 3029330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.
    Palmer AM; Wilcock GK; Esiri MM; Francis PT; Bowen DM
    Brain Res; 1987 Jan; 401(2):231-8. PubMed ID: 2434191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.